Reduce morbidity and mortality in men and women at risk for CVD
2
DON’T LET YOUR
PATIENTS BECOME VICTIMS OF
CARDIOVASCULAR DISEASE
With thanks to the Sandton Fire Department.
Bayer (Pty) Ltd t/a Bayer Schering Pharma; Reg.No.1968/011192/07. 27 Wrench Road, Isando, 1609. Tel (011) 921-5911. L.ZA.GM.10.2010.0065 121848
Bayer is the originator of Aspirin.
References: 1.
Bayer
®
Aspirin Cardio
TM
100 Package Insert.
2.
Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. Prevention of death, myocardial infarction
and stroke by prolonged antiplatelet therapy in various categories of patients.
BMJ
Jan 1994; Vol. 308:81-106.
3.
Cox D, Maree AO, Dooley M, Conroy R, Byrne MF, Fitzgerald DJ. Effect of enteric coating
on antiplatelet activity of low-dose aspirin in healthy volunteers.
Stroke
2006;2153-2158.
4.
Cole AT, Hudson N, Liew LC,
et al
. Protection of human gastric mucosa against aspirin-enteric coating or dose
reduction?
Aliment Pharmacol Ther
. 1999 Feb;13(2):187-93.
S0 Bayer
®
Aspirin Cardio
TM
100. Each tablet contains 100 mg of acetylsalicylic acid (ASA). Reg. No. 31/8/0413. For full prescribing information refer to the package insert approved by the Medicines Regulatory Authority.
l
Persistent thromboxane production has been associated with poor patient outcome.
3
l
Compared to the lower doses (75 mg) of plain Aspirin tablets, 100 mg of enteric-coated Aspirin is recommended to ensure
adequate inhibition of thromboxane production.
3
l
Enteric-coated Aspirin offers effective protection against gastric mucosal
injury by eliminating the injury caused by Aspirin.
4
l
Bayer
®
Aspirin Cardio
TM
100 mg is indicated to reduce the risk of myocardial
infarction and stroke in patients who have had a previous myocardial
infarction, stroke or transient ischaemic attack.
1
l
Bayer
®
Aspirin Cardio
TM
100 mg daily is recommended to reduce the risk
of myocardial infarction in people with cardiovascular
risk factors.
1
Today’s
Prevention.
Tomorrow’s
Protection
1
.
